Characteristics of changes in circulating markers of alveolar epithelial and endothelial injury in acute respiratory distress syndrome with COVID-19

Kentaro Tojo,[1], Natsuhiro Yamamoto[1], Takahiro Mihara[2], Miyou Abe[1], Takahisa Goto[1]

[1] *Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan*

[2] *Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Kanagawa, Japan*

Correspondence to: Kentaro Tojo, Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

e-mail: ktojo-cib@umin.net

Fax: +81-45-787-2916; Tel: +81-45-787-2918

Abstract

The time course and specific contributions of alveolar epithelial and endothelial injury to the pathogenesis of acute respiratory distress syndrome (ARDS) with coronavirus disease (COVID-19) remain unclear. Here, we evaluated the characteristics of circulating markers of alveolar epithelial and endothelial injury in 107 serum samples from nine ARDS patients and eight non-ARDS patients, all with COVID-19. Although both the alveolar epithelial and endothelial injury markers were markedly elevated in the COVID-19 ARDS patients, our data indicate that the endothelial injury, which continues for a longer period than the epithelial injury, seems to be the main contributor to alveolar barrier disruption.

Introduction

In the most severe cases, Coronavirus disease (COVID-19) leads to acute respiratory distress syndrome (ARDS)[1] that is characterised by severe pulmonary oedema with alveolar epithelial and endothelial injuries. Several previous reports have demonstrated that the lungs from ARDS patients with COVID-19 show diffuse alveolar damage[2,3]. However, the time course and specific contribution of alveolar epithelial and of endothelial injury to the pathogenesis of COVID-19 ARDS remain unclear. Better

clarity regarding the pathogenesis will help in improved understanding of the disease, and thus, improved treatment possibilities.

There are several established circulating alveolar tissue injury markers[4]. Evaluating the temporal changes of alveolar tissue injury markers can provide insights regarding the alveolar endothelial and epithelial injuries during COVID-19 ARDS progression. Here, we investigated the levels of a circulating alveolar epithelial injury marker; soluble receptor for advanced glycation end-products (sRAGE), an endothelial injury marker; angiopoietin-2 (ANG-2), and an alveolar barrier permeability indicator; surfactant protein D (SP-D) in serum from COVID-19 patients with or without ARDS.

Methods

The patients diagnosed as COVID-19 by real-time polymerase chain reaction and admitted to Yokohama City University Hospital from January to July 2020 were included in this retrospective observational study (ethics reference number: B200700100). Concentrations of sRAGE, ANG-2, and SP-D in the residual serum samples were measured using enzyme-linked immunosorbent assay kits (human RAGE: DY1145, human ANG-2: DY623, human SP-D: DY1920, R&D systems, MN, USA). We compared the concentrations of these markers on the first or second hospital day

between ARDS and non-ARDS patients. Moreover, we analysed the temporal changes of these markers in ARDS patients.

Comparisons of the data between ARDS and non-ARDS patients were performed using the Mann-Whitney U test. To analyse the correlation of serum levels of sRAGE or ANG-2 with SP-D levels or PaO_2/fraction of inspired oxygen (P/F) ratios, the values of the serum markers were log-transformed to obey normal distribution, and the correlations were evaluated by linear mixed model analysis with random intercepts for individual patients. All statistical analyses were performed using R software (version 4.0.3). Statistical significance level was set at $P < 0.05$.

Results

Clinical characteristics of patients

Nine ARDS and eight non-ARDS patients, all with COVID-19, were included in the study. Patient characteristics are shown in Table 1. Three of the nine in the ARDS group died and all in the non-ARDS group survived. Among patients with ARDS, only one patient developed acute kidney injury, and some patients showed only a small increase in total-bilirubin concentration. Thus, organ dysfunction in the patients was primarily limited to the lungs.

Circulating alveolar tissue injury markers

The initial serum levels of all markers; sRAGE, ANG-2, and SP-D, were significantly higher in the ARDS group than in the non-ARDS group (Table. 1). The temporal changes in these markers in COVID-19 ARDS patients are shown in Fig.1A–C. The peak for serum sRAGE level was observed just after admission (median: day 1, IQR: day 1–3.5) (Fig.1D). In contrast, the peak timings of serum ANG-2 (median: day 4, IQR: day 2.5–6) and SP-D (median: day 5, IQR: day 3–7.5) levels were during a later phase of the disease (Fig.1D).

Linear mixed effect model analysis revealed that the serum ANG-2 levels had a significant positive correlation with the SP-D levels (fixed effect: 0.490, 95%CI: 0.184–0.797, p=0.002) (Fig. 2A) and a significant negative correlation with P/F ratios (fixed effect: -29.9, 95%CI: -56.6–-3.3, p=0.030) (Fig. 2B); however, the sRAGE levels had an opposite correlation with SP-D levels(fixed effect: -0.557, 95%CI: -0.925–-0.189, p=0.004) (Fig. 2C), and there was no significant correlation between sRAGE levels and P/F ratio (fixed effect: -19.9, 95%CI: -51.2–11.3, p=0.215) (Fig. 2D).

Discussion

Our investigation of circulating alveolar tissue injury markers indicates that alveolar barrier tissue injury is a hallmark of COVID-19 ARDS pathogenesis. Interestingly, time courses of changes in alveolar epithelial and in endothelial injury markers were different from each other. The observed serum sRAGE level was highest on admission in most patients with ARDS. In contrast, ANG-2 level reached a peak at later time points. These data suggest that the alveolar epithelial injury in the COVID-19 ARDS already reached the maximum level before hospital admission. Meanwhile, the endothelial injury seems to continue to deteriorate for several days after admission. Moreover, the ANG-2 levels were significantly correlated with the SP-D levels and P/F ratios, suggesting endothelial injury, rather than alveolar epithelial injury, might be a main contributor that leads to deterioration of alveolar permeability during ARDS with COVID-19.

Two reports have previously demonstrated that sRAGE levels in the blood of ARDS patients with bacterial sepsis also peak on the first hospital day[5,6]. Thus, alveolar epithelial injury seems to occur during the initial phase of ARDS progression irrespective of the aetiology. On the other hand, Kumpers et al. reported that circulating ANG-2 levels in patients with bacterial sepsis increased from the baseline level only in the non-survivors, not in the survivors[7]. In our study, the ANG-2 levels increased from baseline in most patients, including survivors, suggesting that SARS-CoV-2

induces more severe endothelial injury than other aetiologies, such as bacterial infection. Several reports have demonstrated that lung vascular thrombosis is a pathological feature of SARS-CoV-2[2,3]. Endothelial injury caused by SARS-CoV-2 infection might be the basal mechanism of thrombosis formation[8].

The underlying mechanism of alveolar epithelial and endothelial injury has not been fully elucidated. SARS-CoV-2 can infect alveolar type 1 and 2 epithelial cells and endothelial cells[9]. On the other hand, inflammatory responses caused by SARS-CoV-2, rather than the SARS-CoV-2 infection itself to the targeted cells, may be the main driver of the alveolar tissue injury[10]. The difference in the peak timing of epithelial and endothelial injury markers suggests that there are distinct mechanisms for injury to each type of cell.

Our data indicate that the targeting the endothelial injury rather than the epithelial injury, may be a potential efficacious approach to overcome ARDS with COVID-19. To obtain insights into the pathogenesis of alveolar tissue injury during COVID-19, further studies to confirm our results using samples from large cohorts are warranted.

Acknowledgements

The authors wish to thank Yokohama City University Department of Emergency Medicine (Prof. Ichiro Takeuchi), Department of Microbiology (Prof. Akihide Ryo), and Center for Novel and Exploratory Clinical Trials for collecting and providing the residual blood samples.

Footnotes

Contributors: KT conducted the study, performed ELISA, analysed data, and wrote the manuscript. NY performed ELISA and reviewed the manuscript. TM supervised statistical data analysis and reviewed the manuscript. MA collected patients' clinical data and reviewed the manuscript. TG supervised the study and reviewed the manuscript

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Patient consent for publication: Waived in view of the retrospective observational nature of the study.

Ethics approval: The study protocol was reviewed and approved by the institutional review board of Yokohama City University Hospital (B200700100).

References

1 Grasselli G, Tonetti T, Protti A, *et al.* Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. *Lancet Respir Medicine* 2020;**8**:1201–8. doi:10.1016/s2213-2600(20)30370-2

2 Polak SB, Gool ICV, Cohen D, *et al.* A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. *Modern Pathol* 2020;**33**:2128–38. doi:10.1038/s41379-020-0603-3

3 Deshmukh V, Motwani R, Kumar A, *et al.* Histopathological observations in COVID-19: a systematic review. *J Clin Pathol* 2020;:jclinpath-2020-206995. doi:10.1136/jclinpath-2020-206995

4 Zee P van der, Rietdijk W, Somhorst P, *et al.* A systematic review of biomarkers multivariately associated with acute respiratory distress syndrome development and mortality. *Crit Care* 2020;**24**:243. doi:10.1186/s13054-020-02913-7

5 Mauri T, Masson S, Pradella A, *et al.* Elevated Plasma and Alveolar Levels of Soluble Receptor for Advanced Glycation Endproducts Are Associated with Severity of Lung Dysfunction in ARDS Patients. *Tohoku J Exp Medicine* 2010;**222**:105–12. doi:10.1620/tjem.222.105

6 Jabaudon M, Blondonnet R, Roszyk L, *et al.* Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study. *Plos One* 2015;**10**:e0135857. doi:10.1371/journal.pone.0135857

7 Kümpers P, Meurs M van, David S, *et al.* Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. *Crit Care* 2009;**13**:R64. doi:10.1186/cc7866

8 Goshua G, Pine AB, Meizlish ML, *et al.* Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *Lancet Haematol* 2020;**7**:e575–82. doi:10.1016/s2352-3026(20)30216-7

9 Schurink B, Roos E, Radonic T, *et al.* Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. *Lancet Microbe* 2020;**1**:e290–9. doi:10.1016/s2666-5247(20)30144-0

10 Tay MZ, Poh CM, Rénia L, *et al.* The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020;**20**:363–74. doi:10.1038/s41577-020-0311-8

Table.1

The clinical characteristics and serum alveolar tissue injury marker levels in ARDS and non-ARDS patients with COVID-19.

	non-ARDS	ARDS	p-Value
Age (years)	49 (30-73)	67 (63-75)	0.2634
Males/Females (number)	6/2	9/0	0.2059
APACHE2 score	7 (4.25-8.75)	11 (9.50-15.50)	*0.0290
P/F ratio at admission,	389 (310-412)	270 (152-336)	*0.0073
Mechanical ventilation use (number)	8	0	<0.0001
Laboratory data on admission			
WBC count (/μL)	4900 (2700-9500)	6200 (5400-7350)	0.7035
Lymphocyte count (/μL)	1109 (965-1569)	643 (321-760)	*0.0003
Platelet count ($\times 10^3$/ μL)	190 (120-306)	206 (170-256)	>0.9999
D-dimer (μg/mL)	0.33 (0.05-0.85)	1.22 (0.65-7.135)	0.0545
CRP (mg/dL)	0.82 (0.15-1.26)	14.62 (8.80-16.82)	*0.0002
Creatinine (mg/dL)	0.72 (0.60-0.84)	0.79 (0.67-0.91)	0.3212
Total bilirubin (mg/dL)	0.55 (0.43-0.70)	0.90 (0.50-1.00)	0.3788
Alveolar tissue injury marker levels on admission			
sRAGE (pg/mL)	701 (344-1148.0)	2680 (1522-5076)	*0.0152

ANG-2 (pg/mL)	231 (64-584)	699 (410-2501)	*0.0464
SP-D (pg/mL)	1771 (458-204)	17542 (7423-22979)	*0.0274

Figure Legends

Figure.1

Temporal changes of (A) sRAGE, (B) ANG-2, and (C) SP-D levels in ARDS patients with COVID-19 for 14 days starting from admission. (D) The peak day of each of the alveolar tissue injury markers. Data were presented as median ± IQR.

Figure.2

The correlations between (A) ANG-2 and SP-D levels, (B) ANG-2 levels and P/F ratios, (C) sRAGE and SP-D levels, and (D) sRAGE levels and P/F ratios. Data were analyzed by linear mixed model analysis with random intercepts for individual patients. Each different colour represents the data from the individual patient.


A
median ± IQR
Individual data
serum sRAGE level(pg/mL)
1×10^5
1×10^4
1×10^3
1×10^2
1×10^1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Day
B
serum ANG2 level (pg/mL)
1×10^5
1×10^4
1×10^3
1×10^2
1×10^1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Day
C
serum SP-D level (pg/mL)
1×10^7
1×10^6
1×10^5
1×10^4
1×10^3
1×10^2
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Day
D
The peak day
15
10
5
0
sRAGE
ANG-2
SP-D


A
LogSPD
LogANG2
P=0.002
B
PFratio
LogANG2
P=0.030
C
LogSPD
LogRAGE
P=0.004
D
PFratio
LogRAGE
P=0.215